You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
興齊眼藥(300573.SZ):收到左氧氟沙星滴眼液的藥品補充申請批准通知書
格隆匯 11-09 16:14

格隆匯11月9日丨興齊眼藥(300573.SZ)公佈,公司於近日收到國家藥監局核准簽發的左氧氟沙星滴眼液《藥品補充申請批准通知書》。藥品通用名稱:左氧氟沙星滴眼液;規格:5ml:24.4mg(以C18H20FN3O4計);劑型:滴眼劑。

左氧氟沙星滴眼液為第三代氟喹諾酮類抗菌藥,本次補充申請是在我公司左氧氟沙星滴眼液(國藥準字H20203593)的基礎上增加的多劑量規格產品。臨牀適應症為:用於治療眼瞼炎、瞼腺炎、淚囊炎、結膜炎、瞼板腺炎、角膜炎以及用於眼科圍手術期的無菌化療法。

目前,國內已有二十多家左氧氟沙星滴眼液上市。原研藥品由日本參天製藥株式會社生產,為多劑量眼用製劑,現已進入中國。左氧氟沙星滴眼液為國家醫保目錄甲類產品。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account